全球医疗科技巨头美敦力(Medtronic)在 5 月 21 日发布 2025 财年业绩的同时宣布重大战略调整:计划将糖尿病业务分拆为独立上市公司,预计 18 个月内通过 IPO 及后续分拆完成。这一决策标志着美敦力自 2021 年传闻以来的战略重组落地,旨在进一步聚焦心血管、神经科学等核心高利润领域,同时为糖尿病业务打造独立创新平台。012025 财年业绩稳健,糖尿病业务表现亮眼美敦力 2025...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.